To overcome these issues, a wholly new and specific approach to targeting RNA, the ribonuclease-targeting chimeras (RIBOTACs) came to the forefront, fusing small molecules with RNA binding ability to a 2'–5'-linked tetra-adenylate conjugate, similar to oligoadenylates produced by cells in response to a viral infection, for RNAse L recruitment, thus converting any inert RNA-binding small molecule into a bioactive RNA degrader, i.e., the RIBOTAC [380]. This evidence concerns the gene RNASEL and viral infectious disease.